Journals / İstanbul Kuzey Klinikleri / 2018 / Cilt: 5 - Sayı: 2

Determination of colistin-related nephrotoxicity and risk factors in intensive care unit

Pages
120–124
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this study, when risk factors for nephrotoxicity wereevaluated, it was found that the presence of nephrotoxicity was greater in cases with chronic obstructive pulmonary disease,malignancy, or abdominal surgery in patients older than 65 years.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: Colistin is a cationic polypeptide antibiotic with a cyclic structure that belongs to the polymyxin group.
📊
Key Findings & Data:It wasbanned from clinical use because of its significant renal side effects, such as nephrotoxicity.
💡
Conclusion & Impact:In this study, when risk factors for nephrotoxicity wereevaluated, it was found that the presence of nephrotoxicity was greater in cases with chronic obstructive pulmonary disease,malignancy, or abdominal surgery in patients older than 65 years.
🔬Design:Review & Systematic Survey
📍Scope:2016 Verileri
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE: Colistin is a cationic polypeptide antibiotic with a cyclic structure that belongs to the polymyxin group. It wasbanned from clinical use because of its significant renal side effects, such as nephrotoxicity. However, the administration ofcolistin has recently been initiated again in the treatment of multi-drug resistant pathogens, such as Acinetobacter baumanniiand Pseudomonas aeruginosa. Nephrotoxicity and neurotoxicity are the main problems encountered in the clinical use ofpolymyxins. The aim of this study was to determine the frequency and risk factors of colistin-related nephrotoxicity in theadult intensive care unit (ICU).METHODS: In this study, a retrospective review of patients who were followed up between January 1 and December 31,2016 and who received colistin treatment in the adult ICU was performed. Retrospective computer records of age, sex, site ofinfection and microorganism breeding, daily creatinine values, and additional diseases were recorded and examined. Nephrotoxicitywas assessed using the Risk, Injury, Failure, Loss, and End-stage kidney disease criteria.RESULTS: A total of 48 patients were included in the study. Of these, 50% were male. The mean age of the patients withnephrotoxicity was 59.73±22.38 years, and the mean age of those without nephrotoxicity was 58.00±22.39 years. A. baumanniwas observed to be the causative microorganism in all patients, and the most frequent infection was pneumonia.Nephrotoxicity was investigated in 54.2% (n=26) of the patients. In this study, when risk factors for nephrotoxicity wereevaluated, it was found that the presence of nephrotoxicity was greater in cases with chronic obstructive pulmonary disease,malignancy, or abdominal surgery in patients older than 65 years. In addition, mortality was greater in those who developednephrotoxicity, although it was not statistically significant.CONCLUSION: In this study, the rate of nephrotoxicity was 54.2% in patients who received colistin in the ICU. Therefore,patients in the adult ICU receiving colistin therapy should be carefully monitored for the development of nephrotoxicity as aside effect.

🔖

Cite This Article

SALİHOĞLU, Z., DERBENT, A., TOKER, M. K., BİÇER, İ. G., İNCİ, A. (2022). Determination of colistin-related nephrotoxicity and risk factors in intensive care unit. İstanbul Kuzey Klinikleri, Cilt: 5 - Sayı: 2, 120–124. https://ajindex.com/articles/551541

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Palabıyık O, Öğütlü A, Toptaş Y. Ventilator-associated pneumonia and causative microorganisms in intensive care unit: a 2-year retrospective analysis. J Turk Soc Intens Care 2016;14:80–5. Biberoğlu K. Intensive Care Unit Infections - Risk Factors, Epidemiology and Prevention. Flora 1997;2:79–84.
  2. Inan D, Saba R, Keskin S, Öğünç D, Çiftçi C, Günseren F, Mamikoğlu L, Gültekin M. Nosocomial Infections in Akdeniz University Intensive Care Units. Yoğun Bakım Dergisi 2002;2(2):129-135.
  3. Camkıran A, Kundakçı A, Araz C, Pirat A, Zeyneloğlu P, Arslan H, et al. Predictors of Multidrug Resistant Acinetobacter Baumannii Infections in Surgical Intensive Care Patients: A Retrospective Analysis. Journal of the Turkish Society of Intensive Care 2011;9: 53–8
  4. Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 2011;53:879–84.
  5. Justo JA, Bosso JA. Adverse reactions associated with systemic polymyxin therapy. Pharmacotherapy 2015;35:28–33.
  6. Tuon FF, Rigatto MH, Lopes CK, Kamei LK, Rocha JL, Zavascki AP. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents 2014;43:349–52.
  7. Koksal I, Kaya S, Gencalioglu E, Yilmaz G. Evaluation of Risk Factors for Intravenous Colistin Use-related Nephrotoxicity. Oman Med J 2016;31:318–21
  8. Spapen H, Jacobs R, Van Gorp V, Troubleyn J, Honoré PM. Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care 2011;1:14. Gaynes R, Edwards JR; National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 2005;41:848–54.
  9. Yilmaz N, Kose S, AguS N, Ece G, Akkoclu G, Kirakli C. Microorganisms Isolated from Blood Cultures of Intensive Care Unit Patients, their Antimicrobial Susceptibility and Etiological Agents in Nosocomial Bacteremia. ANKEM J 2010;24:12–9.
  10. Arslan Zİ, Özbudak E, Türkyılmaz N, Cesur S, Alparslan V, Mirhanoğulları AF, et al. Evaluation of the Use of Colistin on Nephrotoxicity and Mortality in the Intensive Care Unit, Turkiye Klinikleri J Anest Reanim 2015;13:21–4
  11. Kaya M, Tunçel YI, Kuru RN, Menteş S, Ünver S, Çeken S, et al. Retrospective Evaluation of Colistin Associated Nephrotoxicity at Oncology Hospital Intensive Care Unit, J Turk Soc Intens Care 2014;12: 51–6
  12. Inci A, Karabay A, Erus S, Demiraran Y. Nosocomial Infections and Associated Risk